Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11859-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11859-1-AP, RRID:AB_2065902
- Product name
- BRD3 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated BRD3 antibody (Cat. #11859-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Cancer Selective Target Degradation by Folate-Caged PROTACs.
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Light-induced control of protein destruction by opto-PROTAC.
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network.
Liu J, Chen H, Liu Y, Shen Y, Meng F, Kaniskan HÜ, Jin J, Wei W
Journal of the American Chemical Society 2021 May 19;143(19):7380-7387
Journal of the American Chemical Society 2021 May 19;143(19):7380-7387
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, Oguz G, Feng M, Lee PL, Li B, Yang ZH, Chen YF, Lan P, Wu XJ, Yu Q
Nature communications 2021 Jul 21;12(1):4441
Nature communications 2021 Jul 21;12(1):4441
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
Ni M, Li J, Zhao H, Xu F, Cheng J, Yu M, Ke G, Wu X
Oncogene 2021 Apr;40(15):2711-2724
Oncogene 2021 Apr;40(15):2711-2724
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S, Jiang Y, Hong Y, Chu X, Zhang Z, Tao Y, Fan Z, Bai Z, Li X, Chen Y, Li Z, Ding X, Lv H, Du X, Lim SL, Zhang Y, Huang S, Lu J, Pan J, Hu S
Cancer cell international 2021 Apr 22;21(1):230
Cancer cell international 2021 Apr 22;21(1):230
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.
Li Z, Lim SL, Tao Y, Li X, Xie Y, Yang C, Zhang Z, Jiang Y, Zhang X, Cao X, Wang H, Qian G, Wu Y, Li M, Fang F, Liu Y, Fu M, Ding X, Zhu Z, Lv H, Lu J, Xiao S, Hu S, Pan J
Frontiers in oncology 2020;10:574525
Frontiers in oncology 2020;10:574525
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J, Lin W
Frontiers in oncology 2020;10:565820
Frontiers in oncology 2020;10:565820
Light-induced control of protein destruction by opto-PROTAC.
Liu J, Chen H, Ma L, He Z, Wang D, Liu Y, Lin Q, Zhang T, Gray N, Kaniskan HÜ, Jin J, Wei W
Science advances 2020 Feb;6(8):eaay5154
Science advances 2020 Feb;6(8):eaay5154
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP
Haematologica 2019 Jun;104(6):1209-1220
Haematologica 2019 Jun;104(6):1209-1220
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W
Nature medicine 2017 Sep;23(9):1063-1071
Nature medicine 2017 Sep;23(9):1063-1071
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.
Shao Z, Zhang R, Khodadadi-Jamayran A, Chen B, Crowley MR, Festok MA, Crossman DK, Townes TM, Hu K
Nature communications 2016 Mar 7;7:10869
Nature communications 2016 Mar 7;7:10869
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network.
Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, Wu M, Zhou M, Shen S, Li X, Niu Z, Zhang W, Shi L, Xiang B, Lu J, Wang L, Li D, Tang H, Li G
Carcinogenesis 2010 Apr;31(4):559-66
Carcinogenesis 2010 Apr;31(4):559-66
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human brain tissue were subjected to SDS PAGE followed by western blot with 11859-1-AP(BRD3 antibody) at dilution of 1:200
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The BRD3 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human BRD3. This antibody recognizes human, mouse, rat antigen. The BRD3 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
